Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,568,305 papers from all fields of science
Search
Sign In
Create Free Account
refametinib
An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Narrower (1)
RDEA 119
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
P. Vitiello
,
C. Cardone
,
+13 authors
E. Martinelli
Journal of experimental & clinical cancer…
2019
Corpus ID: 59340453
BackgroundPrevious studies showed that the combination of an anti-Epidermal growth factor (EGFR) and a MEK-inhibitor is able to…
Expand
2018
2018
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma
H. Lim
,
P. Merle
,
+24 authors
J. Llovet
Clinical Cancer Research
2018
Corpus ID: 49470932
Purpose: Refametinib, an oral MEK inhibitor, has demonstrated antitumor activity in combination with sorafenib in patients with…
Expand
2017
2017
Integrin-Targeted Hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography for Imaging Tumor Progression and Early Response in Non-Small Cell Lung Cancer1
Xiaopeng Ma
,
Valerie D. Phi Van
,
+13 authors
M. Wildgruber
Neoplasia
2017
Corpus ID: 3637876
2016
2016
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
J. V. Laethem
,
H. Riess
,
+22 authors
B. Childs
Targeted Oncology
2016
Corpus ID: 33466251
BackgroundActivating KRAS mutations are reported in up to 90% of pancreatic cancers. Refametinib potently inhibits MEK1/2, part…
Expand
2015
2015
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
E. Daudigeos-Dubus
,
L. Le Dret
,
+9 authors
B. Geoerger
PloS one
2015
Corpus ID: 14435370
The multikinase inhibitor regorafenib (BAY 73–4506) exerts both anti-angiogenic and anti-tumorigenic activity in adult solid…
Expand
2015
2015
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
A. Adjei
,
D. Richards
,
+17 authors
N. Clendeninn
Clinical Cancer Research
2015
Corpus ID: 29817323
Purpose: To assess the safety and tolerability of the small-molecule allosteric MEK inhibitor refametinib combined with sorafenib…
Expand
Review
2014
Review
2014
MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Caela R. Miller
,
K. Oliver
,
J. Farley
Gynecologic oncology
2014
Corpus ID: 205797901
Highly Cited
2014
Highly Cited
2014
A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
H. Lim
,
J. Heo
,
+15 authors
W. Tak
Clinical Cancer Research
2014
Corpus ID: 797803
Purpose: There is an unmet need for treatment options in hepatocellular carcinoma (HCC). Sorafenib is currently the only approved…
Expand
Review
2013
Review
2013
MEK and the inhibitors: from bench to bedside
Akintunde Akinleye
,
M. Furqan
,
Nikhil Mukhi
,
P. Ravella
,
Delong Liu
Journal of Hematology & Oncology
2013
Corpus ID: 13210265
Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members…
Expand
Highly Cited
2013
Highly Cited
2013
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Robert Schmieder
,
F. Puehler
,
+6 authors
A. Scholz
Neoplasia
2013
Corpus ID: 11672028
OBJECTIVE The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE